At Alexion, our mission is to serve patients and families affected by rare diseases. Since our founding, we have given hope to people who had none and shined a light on those who felt isolated and alone. But we know that fighting rare diseases takes so much more than hope. It requires persistence, dedication, and a relentless pursuit of the highest levels of medical innovation. At Alexion, our goal is to deliver medical breakthroughs where none currently exist.
We have pioneered the complex field of complement biology and delivered solutions to challenges that once seemed impossible for patients with devastating complement-mediated and metabolic disorders. Patients are our Guiding Star, and they inspire us every day to continue to find answers to the most complex scientific challenges because we know lives are at stake.
Alexion has 2,500 dedicated and passionate employees serving patients in 50 countries across the globe. Together, we are building a rewarding place to work and are redefining what it means to live with a rare disease. Our legacy will be measured in the families we serve today and the generations that follow.
Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, and local and regional operations in countries around the world.
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. for the production of Soliris.
We produce pills and we make whole same and not a retail sell......Read More